PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity
Science Advances · 27.02.2026 · 12 (9)
DOI: 10.1126/sciadv.ado7448 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 27.02.2026. Verfasst von Ye Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 511442, P.R. China. Hauptthemen laut MEDLINE: Membrane Proteins, Synthetic Lethal Mutations, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Guangdong Provincial Pearl River Talents Program, National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Activation of the stimulator of interferon genes (STING) pathway drives natural killer (NK) cells and T cells to orchestrate multidimensional antitumor immune responses. While cytosolic DNA accumulation represents a superior endogenous strategy for STING activation, DNA repair machinery substantially constrains its immunogenic potential. Here, we propose a promising therapeutic strategy that leverages proteolysis-targeting chimera (PROTAC)–mediated degradation of PARP1 [poly(ADP-ribose) polymerase 1] and BRD4 (bromodomain-containing protein 4) to induce synthetic lethality, thereby disrupting DNA repair machinery that drives nuclear-to-cytosolic DNA leakage, surpassing the STING activation threshold to ignite cGAS-STING–mediated innate immunity. Our strategy demonstrates superior antitumor efficacy across multiple tumor models, eliciting robust CD8 + T cell– and NK cell–mediated immunity while suppressing pulmonary metastasis progression. This strategic integration of synthetic lethality with an immunogenic stress response establishes a previously unidentified paradigm for expanding broad applications by cGAS-STING–mediated innate immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 511442, P.R. China.
- Guangdong Provincial Key Laboratory of Biomedical Engineering, South China University of Technology, Guangzhou 510006, P.R. China.
- National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, P.R. China.
- Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering and MOE Key Laboratory of Tumor Molecula…
- Key Laboratory of Biomedical Materials of the Ministry of Education, South China University of Technology, Guangzhou 510006, P. R. China.
ORCID-Profile: Ye Liu, Ihsan Ullah, Kewei Wang, Youyong Yuan
Förderung
- Guangdong Provincial Pearl River Talents Program
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- National Key Research and Development Program of China
- Guangzhou Science and Technology Planning Project
Zitieren
APA
Liu, Y., Jiang, M., Ding, M., Ullah, I., Wang, H., Xie, W., Wang, K., & Yuan, Y. (2026). PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity. Science Advances, 12(9). https://doi.org/10.1126/sciadv.ado7448
Vancouver
Liu Y, Jiang M, Ding M, Ullah I, Wang H, Xie W, et al. PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity. Science Advances. 2026;12(9). doi:10.1126/sciadv.ado7448
BibTeX
@article{Liu2026,
author = {Liu, Ye and Jiang, Maolin and Ding, Mengchao and Ullah, Ihsan and Wang, Haiyang and Xie, Wenjiao and Wang, Kewei and Yuan, Youyong},
title = {PROTAC-based synthetic lethality strategy endogenously activates systemic STING to boost antitumor immunity},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {9},
doi = {10.1126/sciadv.ado7448}
}
EUVIMED